Freezing tumor plus two immunotherapies for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether combining a local treatment that freezes a tumor (cryoablation) with two immune “checkpoint” medicines (ipilimumab and nivolumab) can better control unresectable melanoma. It may help when melanoma has grown after prior immune therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have melanoma that cannot be removed with surgery
- Your melanoma has grown after prior immune checkpoint therapy (like pembrolizumab or nivolumab or ipilimumab), and your doctor plans to start ipilimumab plus nivolumab
- You have a tumor spot that doctors believe can be frozen through the skin using imaging guidance
- You have measurable cancer outside the frozen area (so they can track response)
- You can safely receive immunotherapy based on general health tests (including limited steroid use and good blood counts/kidney/liver function)
- You must be able to sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial tests if freezing tumor cells (cryoablation) combined with two drugs (tislelizumab and lenvatinib) can help people whose solid tumors have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This Phase 2 trial studies a specific sequence of immune medicines for people with stage 3 or 4 melanoma that has spread or cannot be removed. It’s designed for melanoma that worsened after prior PD-1 treatment, aiming to shrink tumors and control disease.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.